Innovation Pharmaceuticals Inc (IPIX)

[frenchbroad]

New Brilacidin anti-virus research published 28 December. Alphaviruses and Bunyaviruses.
"Brilacidin has previously been tested in over 500 human subjects across multiple clinical indications where it has been shown to be efficacious and well-tolerated [29,30,31,32,33]. Brilacidin, acting in synergy with other antiviral AMPs or antiviral drugs, may help arrest multiple parts of the viral lifecycle, resulting in better disease outcomes and a reduced risk for antiviral resistance. Deploying brilacidin as part of a prophylactic strategy to prevent early post-entry mechanisms and inhibit the intracellular production of new viral RNA could further prevent severe inflammatory effects observed during later stages of viral infection."
(This article belongs to the Special Issue Emerging Viruses and Antiviral Drugs 2.0)
https://www.mdpi.com/2076-2607/12/1/54